T. B. Bazan Russo

发表

Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer

V. Bazan, D. Fanale, A. Russo, 2022, Cancers.

Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?

D. Olive, S. Vieni, V. Bazan, 2022, Frontiers in Oncology.

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis

S. Vieni, V. Bazan, V. Caló, 2022, Therapeutic advances in medical oncology.

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

V. Bazan, V. Gristina, A. Galvano, 2022, Cancers.

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay

V. Bazan, G. Rinaldi, D. Fanale, 2023, Therapeutic advances in medical oncology.

MUTYH-associated tumor syndrome: The other face of MAP

S. Vieni, V. Bazan, G. Pantuso, 2022, Oncogene.

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study

V. Bazan, E. Francini, L. Castellana, 2022, Cancers.

Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength

A. Russo, V. Bazan, V. Caló, 2022, Frontiers in Oncology.

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer

A. Giordano, S. Vieni, V. Bazan, 2023, BMC Cancer.

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

V. Bazan, A. Florena, V. Gristina, 2023, Frontiers in Oncology.

904MO Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD)

V. Bazan, R. Chiari, A. Toss, 2022, Annals of Oncology.

KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study

V. Bazan, B. Vincenzi, D. de Biase, 2023, The oncologist.

Roles of Tumor-Rducated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family”

V. Bazan, V. Gristina, A. Galvano, 2024, The Journal of Liquid Biopsy.

Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors.

V. Gristina, A. Galvano, L. Incorvaia, 2024, Cancer gene therapy.

The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors

V. Gristina, A. Galvano, A. Russo, 2023, Frontiers in endocrinology.